🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07138729
Recruiting Not applicable

Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis

NCT07138729 · tracked via the Priya Life Science China tracker
Sponsor
Luo Yaping
Phase
Not applicable
Started
2025-05-10
Last updated
2025-08-24

Condition(s) studied

Rheumatoid Arthritis (RA)

Investigational drug(s) / intervention(s)

68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT

68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT: For 68Ga-FAPI PET/CT scan,each patient was injected with 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) body weight of 68Ga-FAPI. PET/CT from skull to feet was performed 60±5 min post-injection. For 99mTc-CTR-FAPI SPECT scan:each patient was injected with 10-20mCi 99mTc-CTR-FAPI . Planar SPECT scan and SPECT/CT were performed 60±5 min post-injection.

Study summary

This study proposes to evaluate 99mTc-CTR-FAPI SPECT imaging as a cost-effective, low-radiation, and widely accessible alternative to 68Ga-FAPI PET/CT for assessing synovial lesions in RA patients, aiming to validate its diagnostic consistency with both PET/CT and physical examinations while correlating imaging findings with clinical disease activity metrics to establish a practical tool for long-term RA monitoring.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age: 18-75 years old; 2. Meet the classification criteria for rheumatoid arthritis of the American College of Rheumatology/European Union for Rheumatology in 2010; 3. The highest disease activity in clinical practice (CDAI or SDAI score Exclusion Criteria: 1. Patients with other autoimmune diseases; 2. Patients with concurrent tumors; 3. Women who are pregnant or planning to become pregnant, women in the preconception period, pregnant and lactating women, and women with child-rearing plans during the study period; Subjects of childbearing age need to take effective contraceptive measures during the research process; 4. Active infection 5. Suffering from claustrophobia or other mental disorders, with poor compliance resulting in inability to cooperate with this researcher; (6) Situations where other researchers consider it inappropriate to participate in this clinical trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting

More Luo Yaping trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07138729 on ClinicalTrials.gov ↗ ← All trials in China